The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II trial of metformin and fluorouracil (MetFU) for patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard treatment.
Vanessa Costa Miranda
No relevant relationships to disclose
Luiza Dib Faria
No relevant relationships to disclose
Maria Ignez Freitas Melro Braghiroli
No relevant relationships to disclose
Monica Jacobs
No relevant relationships to disclose
Jorge Sabbaga
No relevant relationships to disclose
Paulo Marcelo Hoff
No relevant relationships to disclose
Rachel Pimenta Riechelmann
No relevant relationships to disclose